These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 25286972)

  • 41. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
    Munroe M; Kolesar J
    Am J Health Syst Pharm; 2016 Jul; 73(14):1037-41. PubMed ID: 27385701
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [PARP inhibitors--theoretical basis and clinical application].
    Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
    Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PARP Inhibitors for Breast Cancer Treatment: A Review.
    Morganti S; Marra A; De Angelis C; Toss A; Licata L; Giugliano F; Taurelli Salimbeni B; Berton Giachetti PPM; Esposito A; Giordano A; Bianchini G; Garber JE; Curigliano G; Lynce F; Criscitiello C
    JAMA Oncol; 2024 May; 10(5):658-670. PubMed ID: 38512229
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Making the best of PARP inhibitors in ovarian cancer.
    Banerjee S; Kaye SB; Ashworth A
    Nat Rev Clin Oncol; 2010 Sep; 7(9):508-19. PubMed ID: 20700108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Research progresses of the PARP inhibitors for the treatment of cancer].
    He YJ; Liu RH; Ning CQ; Yu NF
    Yao Xue Xue Bao; 2013 May; 48(5):655-60. PubMed ID: 23888686
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
    Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA; Irshad S; Grigoriadis A; Tutt AN
    Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
    Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    Talens F; Jalving M; Gietema JA; Van Vugt MA
    Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
    Sunada S; Nakanishi A; Miki Y
    Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
    Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V
    Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
    Papadimitriou M; Mountzios G; Papadimitriou CA
    Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
    Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
    Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
    Domchek SM
    Clin Adv Hematol Oncol; 2018 May; 16(5):330-332. PubMed ID: 29851928
    [No Abstract]   [Full Text] [Related]  

  • 60. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
    De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
    Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.